Canaccord Initiates Coverage On Else Nutrition With C$6.50 Price Target

This morning, Canaccord Genuity initiated coverage on Else Nutrition (TSXV: BABY) with a C$6.50 price target and a speculative buy rating. This is the first bank to cover Else Nutrition.

Tania Gonsalves, Canaccord’s analyst, says that “Else is building out a portfolio of products centered on this novel nutrition formula. Including sales of infant formula, toddler/children complete nutrition drinks, and complimentary nutrition baby food,” and is forecasting Else’s revenues to go from $1.4 million today to almost $1 billion in 2026, which is roughly a 200% CAGR.

Else Nutrition has developed the first 100% plant-based non-dairy and non-soy formula that mimics breast milk. It’s made up of 92% almonds, buckwheat, and tapioca.

Tania first talks about their balance sheet and cash going forward; she estimates that Else has $29.6 million in cash currently following the raise conducted in October, and estimates that two $30 million equity raises will occur in the future – one each in the fourth quarters of 2021 and 2022. She says that “Based on our forecast burn rate of just under $6.0M per quarter until 2025, when FCF turns positive, we estimate Else has sufficient liquidity to fund operations until Q1/22.”

The next thing she discusses is that their financial forecast leaves room for upside. She breaks down Else’s market share, “At peak, we forecast Else wins 15% of specialty infants, 10% of toddlers, 5% of babies and 2% of children,” in the U.S, EU, Canada, Australia / New Zealand, and/or China.

Gonsalves states, “The global baby food market is worth ~US$75.0B today, with infant formula representing two-thirds of this and growing at 8% Y/Y.” Else will start by selling specialty formulas, and eventually, it will start trying to take market share off the broader organic/vegan population. She adds, “We don’t believe the industry incumbents are working on a comparable non-dairy non-soy formula. If Else’s infant formula is approved, it would likely become a takeout candidate for larger peers, in our view.”

The last thing she talks about is that the management team has deep expertise. The founder Hamutal Yitzhak was previously Head of Consumer Goods at the Neopharm Healthcare Group and Head of Infant Nutrition at Abbott Labs Israel, while the COO Uriel Kesler managed the production of Super Kosher infant formula and baby foods at Shaked Tevel. Lastly, the CTO, Michael Azar co-founded and served as CEO of Materna, a leading infant formula producer in Israel. She says that management owns 47% of the fully diluted shares and as a result are aligned with shareholders.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

BBTV Holdings Sees Canaccord Raise Price Target After Financing

Earlier this week, BBTV Holdings (TSX: BBTV) announced that they closed their upsized 7% convertible...

Saturday, June 19, 2021, 05:14:00 PM

K92 Mining: Canaccord Initiates Coverage With $8.75 Price Target

On January 31st, Canaccord Genuity Capital Markets initiated coverage on K92 Mining Inc. (TSX: KNT),...

Thursday, February 3, 2022, 04:29:00 PM

Cresco Labs: Analyst Q4 2020 Consensus Expectations

Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end...

Thursday, March 25, 2021, 06:00:00 AM

BMO Expects Canadian Banks To Outperform In 2021

In a note sent out to investors on January 3rd, BMO Capital Markets headlines “Bank...

Saturday, January 9, 2021, 01:24:00 PM

Couche-Tard: BMO Unconcerned With Recent Insider Sales

Last week, Alimentation Couche-Tard Inc. (TSX: ATD.B) insiders filed multiple share sales between both the...

Thursday, October 14, 2021, 04:31:00 PM